clinical trial · NCT07285070
Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitis
Non-infectious Anterior UveitisTacrolimus ophthalmic solution
brief summary
The primary objective of the study is to investigate the safety and tolerability of NOV05 eye drops at two concentrations QID in patients with active non-infectious anterior uveitis.
started
Mar 16, 2026
primary completion
Oct 1, 2026
completion
Oct 1, 2026
last updated
Jun 15, 2026
detailed description
This first in-human, phase 2 proof of concept study aims to show that the formulation at two concentrations is safe and well tolerated over a period of 6 weeks.
official title
A Phase 2, Randomized, Double-Masked, Controlled, Proof-of-Concept Study to Evaluate the Safety and Biological Activity of a Water-free Tacrolimus Ophthalmic Solution (NOV05) for the Treatment of Non-Infectious Anterior Uveitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol